Markman M - Search Results

1

Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study.

Markman M, Blessing JA, Alvarez RD, Hanjani P, Waggoner S, Hall K. Markman M, et al. Gynecol Oncol. 2000 Apr;77(1):112-5. doi: 10.1006/gyno.2000.5755. Gynecol Oncol. 2000. PMID: 10739699 Clinical Trial.

2

Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant alpha-interferon.

Markman M, Berek JS, Blessing JA, McGuire WP, Bell J, Homesley HD. Markman M, et al. Gynecol Oncol. 1992 Apr;45(1):3-8. doi: 10.1016/0090-8258(92)90482-x. Gynecol Oncol. 1992. PMID: 1601332 Clinical Trial.

3

Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study.

Markman M, Blessing JA, Major F, Manetta A. Markman M, et al. Gynecol Oncol. 1993 Aug;50(2):191-5. doi: 10.1006/gyno.1993.1191. Gynecol Oncol. 1993. PMID: 8375734 Clinical Trial.

4

Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.

Markman M, Blessing JA, Moore D, Ball H, Lentz SS. Markman M, et al. Gynecol Oncol. 1998 Jun;69(3):226-9. doi: 10.1006/gyno.1998.5016. Gynecol Oncol. 1998. PMID: 9648592 Clinical Trial.

5

Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.

Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC. Markman M, et al. J Clin Oncol. 1998 Aug;16(8):2620-4. doi: 10.1200/JCO.1998.16.8.2620. J Clin Oncol. 1998. PMID: 9704711 Clinical Trial.

6

Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study.

Berek JS, Markman M, Blessing JA, Kucera PR, Nelson BE, Anderson B, Hanjani P. Berek JS, et al. Among authors: markman m. Gynecol Oncol. 1999 Jul;74(1):48-52. doi: 10.1006/gyno.1999.5455. Gynecol Oncol. 1999. PMID: 10385550 Clinical Trial.

7

Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial.

Markman M, Blessing JA, DeGeest K, Morgan M, Look KY, Herzog TJ, Rose PG. Markman M, et al. Gynecol Oncol. 1999 Dec;75(3):444-6. doi: 10.1006/gyno.1999.5640. Gynecol Oncol. 1999. PMID: 10600304 Clinical Trial.

8

Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report.

Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W, Dubeshter B. Markman M, et al. Gynecol Oncol. 1996 Jul;62(1):4-6. doi: 10.1006/gyno.1996.0181. Gynecol Oncol. 1996. PMID: 8690289 Free article. Clinical Trial.

9

Phase 2 trial of moderately high dose single agent mitoxantrone in platinum and paclitaxel-refractory ovarian cancer.

Markman M, Lichtman SM, Homesley H, Kennedy A, Webster K, Ernst S, Omura G, Belinson J. Markman M, et al. Gynecol Oncol. 1998 Jul;70(1):123-6. doi: 10.1006/gyno.1998.5044. Gynecol Oncol. 1998. PMID: 9698488 Clinical Trial.

10

Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.

Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Markman M, et al. Gynecol Oncol. 2000 Oct;79(1):116-9. doi: 10.1006/gyno.2000.5902. Gynecol Oncol. 2000. PMID: 11006042 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

815 results

Search Page

Filters